Worth reading
52Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
611
Millions of yenWording
Conditional
How definitive the wording is.Results for this period
Third quarter2022年6月1日〜2023年2月28日ConsolidatedJapanese GAAPNet Sales41,725Millions of yenYear on year +2.7%Progress 75.0%
Operating profit895Millions of yenYear on year +5.0%Progress 85.3%
Ordinary income936Millions of yenYear on year +3.2%Progress 84.9%
Net income attributable to owners of the parent1Millions of yenYear on year -99.8%Progress 0.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥0.46
Financial position at period-end
Total assets22,495Millions of yen
of which net assets 7,715 Millions of yenEquity ratio 34.2%vs. prior year-end +1.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical device sales 41,613 Millions of yen (YoY +2.8%), Medical Equipment Manufacturing and Sales 211 Millions of yen (YoY -1.1%), Medical Mall Business 50 Millions of yen (YoY -2.4%)
Segment profitMedical device sales 1,574 Millions of yen (YoY +4.5%), Medical Equipment Manufacturing and Sales 10 Millions of yen (YoY -12.2%), Medical Mall Business 0 Millions of yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales55,651 Millions of yen (YoY +0.9%)
Operating profit1,049 Millions of yen (YoY +12.8%)
Ordinary income1,103 Millions of yen (YoY +10.0%)
Net income198 Millions of yen (YoY -71.4%)
Revision to Earnings ForecastNot disclosed → Net Sales 55,651 Millions of yen / Operating profit 1,049 Millions of yen / Ordinary income 1,103 Millions of yen / Net income 198 Millions of yen
Annual Dividend Forecast¥82 → ¥46
Factors Behind Changes in Business Performance
コロナ対策補助金による医療機関の設備投資需要は前年同期より減少したが、検査・手術件数の回復による診療材料の売上が回復・増加し、新型コロナ検査試薬やPPEの消費が継続したことで売上高が増加した。営業利益は売上増加に伴う売上総利益の増加により増加した。親会社株主に帰属する四半期純利益は、貸倒引当金繰入額611百万円の特別損失計上により減少した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income 条件付対価受入益 6 Millions of yen, Gain on sale of investment securities 1 Millions of yen / Extraordinary loss Provision for allowance for doubtful accounts 611 Millions of yen
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End2,553,000 Shares
Treasury Shares at Period-End114 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2022年6月1日〜2023年2月28日 |
| Net Sales | 41,725 Millions of yen (YoY +2.7%) |
| Operating profit | 895 Millions of yen (YoY +5.0%) |
| Ordinary income | 936 Millions of yen (YoY +3.2%) |
| Profit attributable to owners of the parent | 1 Millions of yen (YoY -99.8%) |
| Net income per share | ¥0.46 |
| Equity ratio | End of the current fiscal period 34.2 / End of previous period 33.1 |
| Total assets | 22,495 Millions of yen |
| Net assets | 7,715 Millions of yen |
| Full-year earnings forecast | Net Sales 55,651 Millions of yen (YoY +0.9%) / Operating profit 1,049 Millions of yen (YoY +12.8%) / Ordinary income 1,103 Millions of yen (YoY +10.0%) / Net income 198 Millions of yen (YoY -71.4%) |
| Revision to Earnings Forecast | Not disclosed → Net Sales 55,651 Millions of yen / Operating profit 1,049 Millions of yen / Ordinary income 1,103 Millions of yen / Net income 198 Millions of yen |
| Annual Dividend Forecast | ¥82 → ¥46 |
| Segment revenue | Medical device sales 41,613 Millions of yen (YoY +2.8%), Medical Equipment Manufacturing and Sales 211 Millions of yen (YoY -1.1%), Medical Mall Business 50 Millions of yen (YoY -2.4%) |
| Segment profit | Medical device sales 1,574 Millions of yen (YoY +4.5%), Medical Equipment Manufacturing and Sales 10 Millions of yen (YoY -12.2%), Medical Mall Business 0 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income 条件付対価受入益 6 Millions of yen, Gain on sale of investment securities 1 Millions of yen / Extraordinary loss Provision for allowance for doubtful accounts 611 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 114 Shares |
| Factors Behind Changes in Business Performance | コロナ対策補助金による医療機関の設備投資需要は前年同期より減少したが、検査・手術件数の回復による診療材料の売上が回復・増加し、新型コロナ検査試薬やPPEの消費が継続したことで売上高が増加した。営業利益は売上増加に伴う売上総利益の増加により増加した。親会社株主に帰属する四半期純利益は、貸倒引当金繰入額611百万円の特別損失計上により減少した。 |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医療機関の設備投資需要はコロナ対策補助金の減少により前年同期を下回ったが、検査・手術件数の回復による診療材料の売上回復・増加や、新型コロナ検査試薬・PPEの消費継続により売上高が増加した。営業利益は売上増加に伴う売上総利益の増加による。最終利益の減少は、取引先ジェミック株式会社に生じた債権について貸倒引当金繰入額611百万円を特別損失に計上したため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.